SALT LAKE CITY, May 26, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today presented encouraging preclinical findings for its oral anti-interferon (OAI) candidate, MPI-0485520, at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology being held May 25-28, 2011, at ExCeL London, One Western Gateway, Royal Victoria Dock, London, UK
